Seqens Seqens

X

Find the latest news about Aardvark Therapeutics aggregated by PharmaCompass.com.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Aardvark Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
12707 High Bluff Drive, Suite 200 San Diego, CA 92130-2035
Telephone
Telephone
+1 616-3370-224
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

https://www.globenewswire.com//news-release/2023/08/23/2730472/0/en/GRI-Bio-Enters-into-Asset-Purchase-Agreement-with-Aardvark-Therapeutics-Inc-for-the-Sale-of-Legacy-Asset-ADAIR.html

GLOBENEWSWIRE
23 Aug 2023

https://www.prnewswire.com/news-releases/aardvark-therapeutics-announces-receipt-of-fda-rare-pediatric-disease-designation-for-prader-willi-syndrome-and-expands-the-ongoing-phase-2-clinical-trial-301892147.html

PR NEWSWIRE
03 Aug 2023

https://www.prnewswire.com/news-releases/aardvark-therapeutics-announces-fda-orphan-drug-designation-granted-to-ard-101-a-novel-drug-candidate-for-prader-willi-syndrome-301853812.html

PR NEWSWIRE
20 Jun 2023

https://www.clinicaltrialsarena.com/news/aardvark-therapeutics-ard-101/

CLINICAL TRIALS ARENA
13 Jun 2023

https://www.prnewswire.com/news-releases/aardvark-therapeutics-reports-positive-phase-ii-clinical-data-for-ard-101-301848268.html

PR NEWSWIRE
12 Jun 2023

https://www.prnewswire.com/news-releases/aardvark-therapeutics-inc-announces-the-initiation-of-enrollment-for-three-phase-2-clinical-trials-of-oral-ard-101-301473522.html

PRNEWSWIRE
02 Feb 2022
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY